Focus on cancer curing

Corporate News

Fosun Kite’s Axicabtagene Ciloleucel Granted Priority Review by China NMPA


Corporate News

Fosun Kite’s New Drug Application (NDA) Filing for Axicabtagene Ciloleucel Accepted for Review by China NMPA


About Fosun Kite

Dedicated to the advancement of innovative immune cell therapies

As a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Kite Pharma (a Gilead company) in U.S., Fosun Kite is dedicated to the advancement of innovative immune cell therapy and its commercialization to benefit cancer patients in China.

Our Mission

To become a leader of innovation and
industrialization in immuno cell therapy development

Join us